• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

38
2
2
2
1

COUNTRY

2
1

PRICE

11
14
14
43

PUBLISHED

0
0
1
43

PRODUCT TYPE

41
2

Lymphoma

Lymphoma encompasses a variety of blood cancers of the lymphatic system. Non-Hodgkin’s Lymphoma (NHL) for example, is diagnosed in over 100,000 every year in the US and EU combined. An array of expert reports in our Lymphoma Section enable you to investigate drug development strategies and market trends for NHL, Hodgkin’s Lymphoma, Skin Lymphoma, T-Cell Lymphoma, Indolent Lymphoma and other variants. Investigate key issues such as licensing, R&D, industry alliances, generic drugs (rituximab, bortezomib, doxorubicin, bleomycin, vinblastine, etc.) and the activities of major pharmaceutical players such as Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Show Less Read more

PRODUCT TITLE
Analytical Tool - Lymphoma Analytical Tool - Lymphoma - Product Thumbnail Image

Analytical Tool - Lymphoma

Executive Summary "Analytical Tool: Lymphoma" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphoma R&D and business development. It is also a map...

March 2014
Triple Analysis: Lymphoma, Melanoma and Apoptosis Triple Analysis: Lymphoma, Melanoma and Apoptosis - Product Thumbnail Image

Triple Analysis: Lymphoma, Melanoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Lung Cancer, Lymphoma and Melanoma Triple Analysis: Lung Cancer, Lymphoma and Melanoma - Product Thumbnail Image

Triple Analysis: Lung Cancer, Lymphoma and Melanoma

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

June 2013
FROM
Triple Analysis: Lymphoma, Apoptosis and Peptides Triple Analysis: Lymphoma, Apoptosis and Peptides - Product Thumbnail Image

Triple Analysis: Lymphoma, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

January 2013
FROM
Triple Analysis: Lymphoma, Apoptosis and Antibodies Triple Analysis: Lymphoma, Apoptosis and Antibodies - Product Thumbnail Image

Triple Analysis: Lymphoma, Apoptosis and Antibodies

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies)....

November 2012
FROM
Triple Analysis: Leukemia, Lymphoma and Antibodies Triple Analysis: Leukemia, Lymphoma and Antibodies - Product Thumbnail Image

Triple Analysis: Leukemia, Lymphoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

November 2012
FROM
Triple Analysis: Colorectal Cancer, Lymphoma and Antibodies Triple Analysis: Colorectal Cancer, Lymphoma and Antibodies - Product Thumbnail Image

Triple Analysis: Colorectal Cancer, Lymphoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

November 2012
FROM
Triple Analysis: Lung Cancer, Lymphoma and Antibodies Triple Analysis: Lung Cancer, Lymphoma and Antibodies - Product Thumbnail Image

Triple Analysis: Lung Cancer, Lymphoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

November 2012
FROM
Triple Analysis: Lymphoma, Prostate Cancer and Apoptosis Triple Analysis: Lymphoma, Prostate Cancer and Apoptosis - Product Thumbnail Image

Triple Analysis: Lymphoma, Prostate Cancer and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

September 2012
FROM
Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer - Product Thumbnail Image

Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

September 2012
FROM
09 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities 09 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities - Product Thumbnail Image

09 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in September 2012 All companies include technology, market(s), key...

September 2012
FROM
Triple Analysis: Breast Cancer, Lung Cancer and Lymphoma Triple Analysis: Breast Cancer, Lung Cancer and Lymphoma - Product Thumbnail Image

Triple Analysis: Breast Cancer, Lung Cancer and Lymphoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Lymphoma. Each of these three individual parts is evaluated according to standardized criteria in...

August 2012
FROM
Triple Analysis: Breast Cancer, Lymphoma and Apoptosis Triple Analysis: Breast Cancer, Lymphoma and Apoptosis - Product Thumbnail Image

Triple Analysis: Breast Cancer, Lymphoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

August 2012
FROM
06 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities 06 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities - Product Thumbnail Image

06 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

This report includes details on 39 emerging medical technology companies that have been identified by LSI's in-house research team in June 2012 All companies include technology, market(s), key executive,...

June 2012
FROM
05 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities 05 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities - Product Thumbnail Image

05 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

This report includes details on 41 emerging medical technology companies that have been identified by LSI's in-house research team in May 2012 All companies include technology, market(s), key executive,...

May 2012
FROM
Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts...

May 2012
FROM
Triple Analysis: Lymphoma, Apoptosis and Protein Kinase Inhibitors Triple Analysis: Lymphoma, Apoptosis and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Lymphoma, Apoptosis and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual...

May 2012
FROM
04- 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities 04- 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities - Product Thumbnail Image

04- 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

This report includes details on 37 emerging medical technology companies that have been identified by LSI's in-house research team in April 2012 All companies include technology, market(s), key executive,...

April 2012
FROM
03 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities 03 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities - Product Thumbnail Image

03 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

This report includes details on 61 emerging medical technology companies that have been identified by LSI's in-house research team in March 2012 All companies include technology, market(s), key executive,...

March 2012
FROM
Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer - Product Thumbnail Image

Triple Analysis: Lung Cancer, Lymphoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria...

March 2012
FROM
Loading Indicator

Our Clients

Our clients' logos